about
Perinatal aspects of inherited thrombophilia.Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells.PO-14 - Tumour expression of coagulation proteases of the aPC pathway - a role in the pathogenesis of gynaecological cancers?Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy.LPS induced tissue factor expression in the THP-1 monocyte cell line is attenuated by conjugated linoleic acid.Haemostatic changes and the oral contraceptive pill.Weight-adjusted LMWH prophylaxis provides more effective thrombin inhibition in morbidly obese pregnant women.Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk.Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone.Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes.Low molecular weight heparin for thromboprophylaxis during caesarean section.Thrombin generation assays for optimizing low molecular weight heparin dosing in pregnant women at risk of thrombosis.OC-12 - Peri operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice.A novel serum microRNA panel to discriminate benign from malignant ovarian disease.Peri operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice.PO-24 - Determinants of thrombin generation in gynaecological malignanciesVenous thromboembolism in ovarian cancer: incidence, risk factors and impact on survivalP10. Placental expression of haemostatic and angiogenic markers in preeclampsiaHaemostatic activation in post-menopausal women taking low-dose hormone therapy: Less effect with transdermal administration?The effect of LMWH (tinzaparin) on coagulation and fibrinolytic activation in pregnant women at risk of thrombosisLow molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancyTinzaparin sodium for thrombosis treatment and prevention during pregnancyBlood coagulationThe Effect of Pre-eclampsia on Coagulation and Fibrinolytic Activation in the NeonateNitric oxide in the uteroplacental, fetoplacental, and peripheral circulations in preeclampsiaVitamin E supplementation in hyperlipidaemic patients: effect of increasing doses on in vitro and in vivo low-density lipoprotein oxidationHemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnanciesThe effects of hormone replacement therapy on plasma vitamin E levels in post-menopausal womenThe role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive usersThe in vitro effect of aspirin on increased whole blood platelet aggregation in oral contraceptive usersWhole blood platelet aggregation in moderate and severe pre-eclampsia
P50
Q33810996-7FD785C1-ECC6-4E8C-8067-7799FF5E30F2Q34056033-F0FDBC04-8D3A-4130-83B9-1E5ED9DC3C0AQ39780989-AB934615-84D8-4A36-9122-3D695AE854FCQ39967776-ED3423C8-723D-4B7A-8A06-E1D74003E6AFQ40427276-C73A121F-D2BB-4962-B2C4-558F55BA55B5Q41715413-50CA9117-E29C-4431-B61A-AAA10EF3B7F5Q44495990-201D67D2-9346-4580-93DB-42D70199D1DDQ45150436-9B66693F-87E7-4AE8-A62F-AD676FE72282Q46096868-54A00611-780C-4773-B8A8-E4118E59C1B2Q47180579-B3BB304F-363A-4AF8-9DBA-C543ED4BCAAAQ47251732-828FDD71-54DE-4857-B1FD-330D4BA1AC46Q47380540-F1DF6E63-5F97-423C-B0AF-B70FBDC39959Q48810332-5D4CE14C-572F-47BA-9FDD-CDE673B439E2Q53227286-41F45527-4548-4DDE-9B13-869AC44EB00FQ54130800-DBCBBC25-760B-477B-9330-C552054D1519Q56766296-D14FDFD1-0BD2-48A6-A283-DC0E01BB4434Q61929860-5152CBF9-DB70-4E54-9374-128D180636EEQ61929863-769CC45F-9C91-4CCD-88E7-AAD124921581Q61929866-97B94010-70FE-4D28-94D1-05101EFB9266Q61929871-07907515-228C-400D-B2D2-2501A6882A62Q61929872-6FA618DA-64B4-4BC8-A487-29D33E1D78B6Q61929873-57254E8B-6CCF-45F0-9F1A-9BF1AC2D14BFQ61929876-5C52D613-A5AA-4B19-BF91-D39E28BAD790Q61929880-D0F7143E-58F7-49D7-BACE-D9FBF108F3E0Q61929885-E9A71A58-51E7-4D9A-877F-C2BA22FE83DEQ61929886-D64564FB-5AA8-4276-9274-626572BB6443Q61929887-48BDFA24-2905-41B1-961D-56997FD71990Q61929890-F1DE9903-3D67-459A-A483-7D8F58ABE2D6Q61929891-FCE752AB-E364-4B01-8BF4-1C917BE44B81Q61929893-E7EEDD74-B86B-4CFD-BC8B-5FD0A3FF87DBQ61929894-2EB224E1-9362-47D2-8E64-32430151BDED
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lucy Norris
@ast
Lucy Norris
@en
Lucy Norris
@es
Lucy Norris
@nl
Lucy Norris
@sl
type
label
Lucy Norris
@ast
Lucy Norris
@en
Lucy Norris
@es
Lucy Norris
@nl
Lucy Norris
@sl
prefLabel
Lucy Norris
@ast
Lucy Norris
@en
Lucy Norris
@es
Lucy Norris
@nl
Lucy Norris
@sl
P106
P1153
7007018085
P21
P31
P496
0000-0001-7862-3230